Expired patents mean big losses for Big Pharma

Jennifer Collins Apr 19, 2011
HTML EMBED:
COPY

Expired patents mean big losses for Big Pharma

Jennifer Collins Apr 19, 2011
HTML EMBED:
COPY

Jeremy Hobson: We’re getting a look at the health of the pharmaceutical industry today with earnings from companies like Johnson & Johnson, and Forest Laboratories. Analysts are seeing a bit of a downer from the drug companies this quarter.

Marketplace’s Jennifer Collins reports.


Jennifer Collins: Patents are about to expire on several blockbusters: Plavix, Zyprexa and cholesterol drug Lipitor. That last one is the bestselling drug in the world.

Lipitor advertisement: I trust my heart to Lipitor.

But millions of people may start trusting their hearts to generics once Pfizer loses that patent.

Chris Bowe: Thus they meet what they call a patent cliff.

Analyst Chris Bowe says Pfizer’s sales of Lipitor could drop by half in as little as a year. So Pfizer and other pharmaceutical companies need to have a stream of drugs in development. Miller Tabak’s Les Funtleyer says, these days, there’s been a shortage.

Les Funtleyder: Drugs are going generic faster than pharmaceutical companies can create new ones.

So what they can’t create, they buy.

Funtleyder: Which is why you’ve seen a lot of acquisitions.

And Funtleyder says that is likely to continue.

I’m Jennifer Collins for Marketplace.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.